Cochrane Abstracts
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer Edited (no change to conclusions)
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer Edited (no change to conclusions) is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer Edited (no Change to Conclusions)." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Vitamin_D_and_vitamin_D_analogues_for_preventing_fractures_in_post‐menopausal_women_and_older_men_Edited__no_change_to_conclusions___comment_added_to_review. Accessed 21 March 2023.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer Edited (no change to conclusions). Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Vitamin_D_and_vitamin_D_analogues_for_preventing_fractures_in_post‐menopausal_women_and_older_men_Edited__no_change_to_conclusions___comment_added_to_review. Accessed March 21, 2023.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer Edited (no change to conclusions). In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Vitamin_D_and_vitamin_D_analogues_for_preventing_fractures_in_post‐menopausal_women_and_older_men_Edited__no_change_to_conclusions___comment_added_to_review
Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer Edited (no Change to Conclusions) [Internet]. In: Cochrane Abstracts. [cited 2023 March 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Vitamin_D_and_vitamin_D_analogues_for_preventing_fractures_in_post‐menopausal_women_and_older_men_Edited__no_change_to_conclusions___comment_added_to_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer Edited (no change to conclusions)
ID - 431195
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Vitamin_D_and_vitamin_D_analogues_for_preventing_fractures_in_post‐menopausal_women_and_older_men_Edited__no_change_to_conclusions___comment_added_to_review
DB - Evidence Central
DP - Unbound Medicine
ER -
